Jason Snape

Over the past 25 years, I have played a pivotal role in advancing the environmental and health research, innovation, and global engagement working at AstraZeneca (former Global Head of Environmental Protection and member of its Global Sustainability and UK Leadership Teams), for the European and International pharmaceutical industry trade associations (Efpia and IFPMA), for the Federation of European Chemical Industry Associations (CEFIC) and for the UKRIs Natural Environment Research Council (NERC).  I am a values-driven person that inspires others, strives for continual innovation and collaboration to deliver real-world impacts that help communities, businesses, and our planet. I have a career investigating the complex interdependencies between environment and human health, that has influenced business best practice and environmental policy at local, national, and international levels.  My research has been used in UKRI REF Impact case studies and I sat on the REF committee that assessed the impact of UKRI-NERC Facilities.

I have built collaborations with business, industry, government agencies and third sector organisations to enhance the uptake and application of research in environmental policy and business best practice.  These collaborative partnerships have been in several areas that relate to environmental and human health driving innovation and systems level thinking to tackle some of the critical challenges we are facing.  Research themes include:

• Using metagenomic and machine learning approaches to assess the persistence, biodegradation and mobility of chemicals earlier in sustainable product development

• Driving recognition of the importance of the environmental dimension of antimicrobial resistance (AMR) and assessing the effectiveness of proposed environmental stewardship and mitigation measures

• Determining minimum selective concentrations for antibiotic resistence, co-selective agents and environmentally relevant mixtures

• Managing the human and environmental health risks of drug manufacture and chemical production across value chains

• Assessing the environmental sustainability of access to healthcare and medicines in low- and middle-income countries

• The impact of climate change on public health, environmental pollution management

• Integrating the climate and wider environmental footprint of medicinal products to help deliver patient centric net zero healthcare

• Determining the overall persistence and environmental risks associated with next generation low global warming potential HFC/ HFA alternatives and their degradation products